Has Novateor Resear. declared dividend?

No Dividend History Available

When is the next results date for Novateor Resear.?

No Upcoming Board Meetings

Is Novateor Resear. overvalued or undervalued?

As of May 19, 2025, Novateor Research is rated as risky and overvalued, with a PE Ratio of 27.80, negative ROCE of -4.59%, and ROE of 0.38%, despite outperforming the Sensex with an 18.9% return over the past year.

As of 19 May 2025, the valuation grade for Novateor Research has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company is currently deemed overvalued. Key ratios include a PE Ratio of 27.80, a Price to Book Value of 3.51, and an EV to Sales ratio of 23.81, which suggest that the stock is priced high relative to its earnings and book value.<BR><BR>In comparison to its peers, Novateor Research's PE Ratio stands in stark contrast to Max Healthcare Institute Ltd., which has a PE of 100.29, and Apollo Hospitals Enterprise Ltd., with a PE of 69.03, both categorized as very expensive. This highlights the relative valuation concerns for Novateor Research, especially given its negative ROCE of -4.59% and ROE of 0.38%. While Novateor has outperformed the Sensex over the past year with a return of 18.9% compared to the Sensex's 7.55%, the underlying financial metrics suggest caution for potential investors.

What is the technical trend for Novateor Resear.?

As of May 15, 2025, Novateor Research's technical trend is neutral, with no clear bullish or bearish indicators, as the stock price remains unchanged at 57.50 despite strong long-term performance relative to the Sensex.

As of 15 May 2025, the technical trend for Novateor Resear has changed from mildly bearish to does not qualify. Given the lack of specific technical indicators such as MACD, RSI, or moving averages, and the current price remaining unchanged at 57.50, there is insufficient data to form a definitive bullish or bearish stance. The stock's performance relative to the Sensex shows strong returns over the longer term, but current technical analysis does not provide a clear direction.

Who are the peers of the Novateor Resear.?

Novateor Resear.'s peers include Indong Tea Co, Hipolin, Sinnar Bidi Udy., KMG Milk Food, Paramount Cosmet, Tasty Dairy, BKV Industries, and Shanthala FMCG. Most peers exhibit below-average management risk, growth, and capital structure, with KMG Milk Food showing the highest 1-year return at 44.01% and Novateor Resear. at 4.91%.

Peers: The peers of Novateor Resear. are Indong Tea Co, Hipolin, Sinnar Bidi Udy., KMG Milk Food, Paramount Cosmet, Tasty Dairy, BKV Industries, and Shanthala FMCG.<BR><BR>Quality Snapshot: Below Average management risk is observed at Indong Tea Co, Hipolin, Sinnar Bidi Udy., Paramount Cosmet, Tasty Dairy, Shanthala FMCG, and Novateor Resear., while KMG Milk Food and BKV Industries do not qualify. Below Average growth is found at Indong Tea Co, Hipolin, Sinnar Bidi Udy., Paramount Cosmet, Shanthala FMCG, and Novateor Resear., while Tasty Dairy has Average growth and KMG Milk Food and BKV Industries do not qualify. Below Average capital structure is noted for Indong Tea Co, Hipolin, Sinnar Bidi Udy., Paramount Cosmet, Tasty Dairy, Shanthala FMCG, and Novateor Resear., with KMG Milk Food and BKV Industries not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KMG Milk Food at 44.01%, while the lowest is Indong Tea Co at -44.29%. Novateor Resear. has a 1-year return of 4.91%, which is higher than Indong Tea Co but lower than KMG Milk Food. Additionally, the six-month return is negative for Indong Tea Co, Hipolin, Paramount Cosmet, and Shanthala FMCG.

Who are in the management team of Novateor Resear.?

As of March 2020, the management team of Novateor Resear includes Navdeep Subhashbhai Mehta (Managing Director & CFO), Tejal Navdeep Mehta (Whole-time Director), and four independent directors: Anand Rajendra Shah, Chintan Pankaj Shah, Sindhav Vipulbhai, and Jitin Jaysukh Doshi (Non-Executive Director). This diverse team guides the company's governance and strategy.

As of March 2020, the management team of Novateor Resear includes the following individuals:<BR><BR>1. Navdeep Subhashbhai Mehta - Managing Director & CFO<BR>2. Tejal Navdeep Mehta - Whole-time Director<BR>3. Anand Rajendra Shah - Independent Director<BR>4. Chintan Pankaj Shah - Independent Director<BR>5. Sindhav Vipulbhai - Independent Director<BR>6. Jitin Jaysukh Doshi - Non Executive Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What does Novateor Resear. do?

Novateor Research Laboratories Ltd is a micro-cap company in the FMCG industry, incorporated in 2011 and converted to a public company in 2019. As of March 2020, it reported net sales of 1 Cr and a market cap of INR 25 Cr, with a P/E ratio of 24.00.

Overview:<BR>Novateor Research Laboratories Ltd operates in the Fast-Moving Consumer Goods (FMCG) industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as Novateor Research Laboratories Private Limited in 2011 and later converted to a Public Limited Company with its name changed to Novateor Research Laboratories Limited on April 22, 2019. The latest quarterly results reported net sales and net profit for the period ending March 2020.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1 Cr (Quarterly Results - Mar 2020)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2020)<BR>- Market-cap: INR 25 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 24.00<BR>- Industry P/E: 81<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.13<BR>- Return on Equity: 1.01%<BR>- Price to Book: 3.17<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Novateor Resear.?

The top shareholders of Novateor Resear include Navdeep Subhashbhai Mehta with 29.56%, individual investors with 26.45%, and public shareholder Jitin Jaysukhlal Doshi at 3.85%. There are currently no mutual funds or foreign institutional investors holding shares in the company.

The top shareholders of Novateor Resear include the promoters, with Navdeep Subhashbhai Mehta holding the largest stake at 29.56%. Individual investors collectively own 26.45% of the company. The highest public shareholder is Jitin Jaysukhlal Doshi, who holds 3.85%. Notably, there are no mutual funds or foreign institutional investors currently holding shares in the company.

How big is Novateor Resear.?

As of 21st July, Novateor Research Laboratories Ltd has a market capitalization of 24.00 Cr and reported Net Sales of 0.13 Cr with a Net Profit loss of 0.02 Cr for the latest quarter ending March 2020. As of March 2024, Shareholder's Funds are 8.76 Cr and Total Assets are 10.46 Cr.

As of 21st July, <BR><BR>Market Cap: Novateor Research Laboratories Ltd has a market capitalization of 24.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest quarter ending March 2020, the company reported Net Sales of 0.13 Cr and a Net Profit loss of 0.02 Cr.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2024, with Shareholder's Funds amounting to 8.76 Cr and Total Assets of 10.46 Cr.

Which are the latest news on Novateor Resear.?

Why is Novateor Resear. falling/rising?

As of 27-Nov, Novateor Research Laboratories Ltd's stock price is at 25.10, showing no change and underperforming its sector by 2.15%. The stock is trading below its moving averages and has seen a 37.5% drop in delivery volume, indicating a bearish trend and reduced investor interest.

As of 27-Nov, Novateor Research Laboratories Ltd's stock price is currently at 25.10, with no change from the previous trading session. The stock has underperformed its sector by 2.15%, indicating a decline in relative performance. Additionally, the stock has exhibited erratic trading patterns, having not traded on 5 out of the last 20 days. This inconsistency may contribute to investor uncertainty.<BR><BR>Moreover, Novateor Research Laboratories Ltd is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. There has also been a notable decrease in investor participation, with delivery volume dropping by 37.5% compared to the 5-day average, suggesting reduced interest from investors. Despite being liquid enough for trade, these factors collectively indicate that the stock is currently experiencing a downward trend.